UK Investment Guides Loader
trending now

Please scroll down to view and accept privacy policy to continue

OUR PRIVACY AND COOKIE POLICY

This Privacy and Cookie Policy states what we will do with your Personal Data once you have submitted your details to the site. By submitting your details, you agree to the principles of this policy. We comply with the Data Protection Act 1998. Any information you give to UK Investment Guides will be held with the utmost care and will not be used in ways that you have not consented to. If you have any requests concerning your personal information or any queries with regard to these practices please contact our Data Manager via email: info@ukinvestmentguides.com

Collection of Information

We collect personal information in a number of different ways. These include email enquiry forms which can be found on our contact us page, through data capture forms found on guide or report download pages and through cookies. You can find out more about what cookies are and why we use them further down this document.

Use of Personal Information

Your personal data will be used by UK Investment Guides to communicate with you. This will take the form of emailing you our product newsletters, sending you specially selected Third Party advertising offers, or communicating with you regarding our service so long as you have opted-in to receiving any of the former. Your personal information will not be used for any purpose not directly related to UK Investment Guides business offering. At any point you can unsubscribe from any or all of our communications by clicking the unsubscribe link which we make available on all our communications. If you have problems doing this you can contact us on 020 3674 7958 and ask to speak with our Data Manager or email info@ukinvestmentguides.com

Data Capture Forms

We will send you information according to the preferences you submitted via our data capture form. If you would like to change these preferences at any point, please email us at info@ukinvestmentguides.com or call us on 020 3674 7958. Alternatively, you can also write to us: Data Manager, 11A, Challenge House, 616 Mitcham Road, Croydon, CR0 3AA

Marketing

On occasion we may market to you products and services related to UK Investment Guides business offering (including updates to our service offering) and also offers from carefully selected advertisers where you have opted-in to receiving such communications. If at any point you would like to opt-out of receiving communications from us, or you would like to change the channels that we use to contact you, please contact us at info@ukinvestmentguides.com. Additionally, you can unsubscribe from any or all of our communications by clicking the unsubscribe link that is available on all of our communications.

Please note that we can only unsubscribe e-mail addresses we know about and not any forwarding or linked addresses from whose accounts a request may be received. To ensure you stop receiving our e-mails, please provide the original e-mail address you signed up with or all addresses you think we may hold.

Other Websites

Our website may contain links to other websites that are outside our control and are not covered by this Privacy Policy. If you access other sites using the links provided, the operators of these sites may collect information from you that will be used by them in accordance with their privacy policies which may differ from ours.

Subject Access Requests

You have the right to see what personal data we hold about you. To obtain a copy of the personal information that we hold about you, please write to us: please email us at info@ukinvestmentguides.com . Alternatively, you can also write to us: Data Manager, 11A, Challenge House, 616 Mitcham Road, Croydon, CR0 3AA.

Internet-based Transfers

Given that the Internet is a global environment, using it to collect and process personal data necessarily involves the transmission of data on an international scale. This means, for instance, that data you pass to us may be processed outside the European Economic Area, although the data will always be held securely and in-line with the requirements of UK data protection legislation. By communicating electronically with us, you acknowledge and consent to our processing of personal data in this way.

Amendments

Please note that this privacy policy is subject to change from time to time. It was last updated in April 2017.

I agree with UK Investment Guides Privacy Policy:  

Immunocore raises $273m as it launches US flotation

written by Bella Palmer
ipo

The company has also raised $15m in a private placement, taking the current investment raise to £200m

Immunocore’s flotation in the US has raised $258 million. The pricing of its initial public offering on the Nasdaq in New York, managed by investment banks Goldman Sachs, JP Morgan and Jefferies, is $158m higher than it expected in January.

The Oxford-based company, which delivers biological therapies that have the potential to transform the lives of people with serious diseases including cancer, has also raised $15m in a concurrent private placement. That takes the investment raised today to £200m.

In January Immunocore revealed a £55m Series C funding round and closing of a £74m senior secured loan facility with Oxford Finance LLC.

The news followed positive Phase 3 trial interim analysis data for its lead programme tebentafusp, which aims to help patients with metastatic uveal melanoma, a form of eye cancer.  

The investments are intended to fund a potential commercial launch of tebentafusp.

CEO Bahija Jallal said last month: This successful financing represents another validating milestone for Immunocore as we continue our pioneering work in the field of soluble, bispecific TCR immunotherapies to treat a broad range of diseases.  

The support of our new and existing investors represents a further endorsement of the potential of our powerful technology platform, Jallal said.

She said, following the recent positive Phase 3 data for tebentafusp, we are working to progress this investigational agent through the regulatory process as a potential new treatment to metastatic uveal melanoma patients with a high unmet need.

Immunocore believes tebentafusp could be the first new therapy for the treatment of metastatic uveal melanoma in 40 years. 

Commenting on the IPO, Darragh Lyons, CEO of investor Malin, said: Immunocore’s IPO is a significant milestone for the company. It expects to have several important clinical milestones during the second-half of 2021 and during 2022.

Important:

This article is for information purposes only.

Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.

There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.

Share this post with friends!

Related Posts